Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II clinical trial (RCT), offering an early signal that could reshape how advanced ...
Tirzepatide, which is marketed as Zepbound for chronic weight management, is a dual GIP and GLP-1 receptor agonist that has ...
Digitally delivered behavior-change prompts plus short videos can boost GLP-1 users’ expectations to adopt healthy lifestyle behaviors.
First High-Quality Study to Explore A Carnivore-Style Diet in Managing Metabolic Health, WhichAffects Millions of AmericansOver one-third of U.S. adults – or 115.2 million Americans – are prediabetic, ...
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy ...
High-dose Vitamin D doesn't reduce acute COVID severity but shows a promising signal for reducing Long COVID and brain fog.
A randomized controlled trial (RCT) published today in Psychological Medicine demonstrates a significant and clinically relevant reduction in ADHD symptoms in adults using the digital therapy "attexis ...
Initial treatments are underway in randomized study of Acorn’s personalized autologous injectable for improving facial ...
Public health has its own bracket of champions: breakthroughs that eliminated deadly diseases, revolutionized surgery, and opened entirely new doors in medicine. From vaccines to mRNA technology, ...
US-based biopharmaceutical company Spinogenix has concluded the enrolment of patients in its Phase II clinical trial of tazbentetol (previously known as SPG302), a synaptic regenerative treatment for ...
The prescription drug leucovorin is getting a label update, though it’s not what that the US Food and Drug Administration ...
MFDS IND approval enables a multicenter, randomized, double-blind, vehicle-controlled phase 2 study in ~150 DED patients, randomized 1:1:1 to two dosing arms versus control over 12 weeks. Prior phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results